Meeting
2023 ASCO Annual Meeting
Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy for newly diagnosed glioblastoma.
Authors
Samuel Ryu
Stony Brook University School of Medicine, Stony Brook, NY
Samuel Ryu , Xiaobu Ye , Jeffrey J. Olson , Tom Mikkelsen , Lev Bangiyev , Glenn Jay Lesser , Tracy Batchelor , Louis B. Nabors , Serena Desideri , Tobias Walbert , Stuart A. Grossman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT00045565
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2061)
DOI
10.1200/JCO.2023.41.16_suppl.2061
Abstract #
2061
Poster Bd #
418
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).
First Author: Frank Saran
Poster
2021 ASCO Annual Meeting
Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma.
First Author: Louis B. Nabors
Poster
2019 ASCO Annual Meeting
Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
First Author: Warren P. Mason
Poster
2019 ASCO Annual Meeting
A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma.
First Author: Jiayi Huang